The increasingly likely possibility that SARS-CoV-2 arose from a systematic gain-of-function study on the emergence of human pathogens from wildlife reservoirs does not invalidate the implications of the study.
Along with the post-exposure prophylaxis trials, this further indicates genuine antiviral activity in vivo for ivermectin (not merely anti-inflammatory).